1,045 results on '"Selenica A."'
Search Results
102. Histologic and genomic characterization of a primary mucinous carcinoma of the skin
103. PR050/#373 Clinicopathologic and genomic analysis of uterine serous carcinomas arising from endometrial hyperplasia
104. Supplementary Figures S1-S6 from Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications
105. Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures and actionable driver mutations
106. Clinicopathologic Characteristics of PANDAS in a Young Adult: A Case Report
107. The Contribution of Isometric and Stretching Exercises to Youth Postural Behavior Improvement in the Physical Education Program
108. Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases
109. The genomic landscape of metastatic histologic special types of invasive breast cancer
110. Comprehensive analysis of germline drivers in endometrial cancer
111. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation
112. Abstract 1635 The role of Spermidine/spermine N1-acetyltransferase 1 and the polyamine stress response in TDP-43 proteinopathies
113. From Class to Identity: The Politics of Education Reform in Former Yugoslavia, by Jana Bacevic. Budapest–New York: Central European University Press, 2014, pp. 235.
114. Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications
115. Data from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
116. Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
117. Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
118. Analysing a non-IR field through IR lenses. Education in post-conflict Kosovo
119. Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking
120. The scientific system in the Global South in an emerging multipolar world
121. Actors and Sites for Knowledge Production on Radicalisation in Europe and Beyond
122. 12 Genetic analysis of primary and recurrent adult granulosa cell tumors of the ovary
123. 9 Genomic profiling of recurrent “ultra-low risk” endometrial cancer
124. Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas
125. Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
126. KIT genetic alterations in breast cancer.
127. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
128. The scientific system in the Global South in an emerging multipolar world
129. Abstract 3375: Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq
130. Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
131. Abstract 4284: Enhancing subclonal reconstruction algorithm for resolving complex tumor phylogenies from multi-sample tumor DNA sequencing
132. Supplementary Data from Cancer-Causative Mutations Occurring in Early Embryogenesis
133. Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
134. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers
135. Supplementary Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles
136. Supplementary Tables from Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases
137. Supplementary Figure S1 from Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases
138. Supplementary Table S2 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
139. Supplementary Figure S2 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
140. Supplementary Figures from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
141. Data from Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases
142. Supplementary Figure Legends from Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
143. Supplementary Data from Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome
144. Supplementary Materials from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
145. Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
146. Supplementary methods and Figure Legends from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
147. Supplementary Methods from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
148. Supplementary Figure S5 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
149. Supplementary Table S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
150. Supplementary Figure S1 from Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.